Does Adjuvant Chemotherapy Dose Modification Have an Impact On the Outcome of Patients diagnosed with Advanced Stage Ovarian Cancer? An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advancedstage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecol Oncol
Hauptverfasser: Olawaiye, Alexander B., Java, James J., Krivak, Thomas C., Friedlander, Michael, Mutch, David G., Glaser, Gretchen, Geller, Melissa, O’Malley, David M., Wenham, Robert M., Lee, Roger B., Bodurka, Diane C., Herzog, Thomas J., Bookman, Michael A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151871/
https://ncbi.nlm.nih.gov/pubmed/30135020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.07.021
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge